Location History:
- Bracknell, EN (1977)
- Bracknell, GB (1978 - 1981)
- Berks, GB (1990)
- Bershire, GB (2002)
- Reading, GB (1988 - 2007)
- Hampshire, GB (2008)
- Basingstoke, GB (2008 - 2012)
- Berkshire, GB (2016)
Company Filing History:
21 out of 158 
21 out of 4,447 
2 out of 8 Years Active: 1977-2016
Title: David Edward Tupper: Pioneering Inventor in Biomedical Research
Introduction:
David Edward Tupper, an exceptional innovator based in Reading, GB, has made significant contributions to the field of biomedical research. With an impressive record of 36 patents to his name, Tupper is a renowned figure in the industry. This article explores his latest patents, as well as highlights from his career and collaborations.
Latest Patents:
Among David Edward Tupper's latest patents are two groundbreaking inventions: "Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist" and "1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulators."
The first patent introduces novel mGlu2 agonists that have potential applications in treating bipolar disorder, schizophrenia, and generalized anxiety disorder. These compounds have the capability to stimulate the mGlu2 receptor, which plays a crucial role in brain function and mental health.
The second patent revolves around compounds that act as CB1 receptor modulators, functioning as inverse agonists. These compounds have shown promise in reducing body weight in mammals and alleviating cognitive impairment associated with schizophrenia. Additionally, they hold significant potential to mitigate treatment emergent weight gain observed during antipsychotic treatments.
Career Highlights:
Throughout his illustrious career, David Edward Tupper has been associated with distinguished companies such as Lilly Industries, Inc., and Eli Lilly and Company. Working within these influential organizations, Tupper has demonstrated his expertise in the field of biomedical research.
His exceptional patent portfolio reflects his deep understanding of critical therapeutic targets and a relentless drive to advance pharmaceutical science. Tupper's work has paved the way for innovative treatments addressing various mental health conditions, including bipolar disorder, schizophrenia, and cognitive impairments associated with these conditions.
Collaborations:
Collaboration often plays a pivotal role in groundbreaking innovations. Tupper has cultivated productive partnerships with esteemed professionals, including Terrence M Hotten and Jiban Kumar Chakrabarti. These collaborations have fostered an environment of knowledge-sharing and synergy, resulting in remarkable advancements in biomedical research.
Conclusion:
David Edward Tupper's contributions to the field of biomedical research are remarkable, backed by an impressive array of patents. His latest patents underscore his commitment to revolutionizing mental health treatments, particularly with regards to bipolar disorder, schizophrenia, and associated cognitive impairments.
With a career spanning prestigious companies like Lilly Industries, Inc., and Eli Lilly and Company, Tupper is recognized for his expertise and profound dedication to advancing pharmaceutical science. Through his successful collaborations, he has harnessed the power of collective knowledge to drive disruptive innovation in the biomedical field.
David Edward Tupper's pioneering work remains invaluable in furthering our understanding and treatment of mental health conditions, positively impacting countless lives around the globe.